{
  "guideline": {
    "id": "PA166265341",
    "name": "Annotation of DPWG Guideline for lamotrigine and HLA-B",
    "source": "DPWG",
    "version": 7,
    "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166265341",
    "relatedChemicals": [
      {
        "id": "PA450164",
        "name": "lamotrigine",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA35056",
        "name": "major histocompatibility complex, class I, B",
        "symbol": "HLA-B"
      }
    ],
    "recommendation": true
  },
  "recommendations": [
    {
      "id": "PA166299278",
      "name": "Recommendation PA166299278",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA450164",
          "name": "lamotrigine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061641,
        "html": "<ul>\n<li>Carefully weigh the risk of SJS/TEN against the benefits.</li>\n<li>Avoid lamotrigine if an alternative is available.\n<ul>\n<li>Carbamazepine carries a much higher risk of SJS/TEN in these patients and is therefore not an alternative.</li>\n<li>A similar risk has been reported for phenytoin as for lamotrigine.</li>\n<li>The same applies to oxcarbazepine, but the most severe forms (SJS/TEN overlap and TEN) have not been observed with oxcarbazepine.</li>\n</ul>\n</li>\n<li>If it is not possible to avoid these products, advise the patient to report any rash immediately.</li>\n</ul>\n"
      },
      "implications": [
        "The life-threatening cutaneous side effect Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) occurs more often in patients with this genetic variation. Based on the estimated risk for all patients and the increase by a factor 3.6 for patients with this genetic variation, the risk of lamotrigine-induced SJS/TEN in patients with HLA-B*1502 is estimated at 0.4%."
      ],
      "lookupKey": {
        "HLA-B": "*15:02 positive"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166299277",
      "name": "Recommendation PA166299277",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA450164",
          "name": "lamotrigine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061640,
        "html": "<p>The guideline does not provide a recommendation for lamotrigine in patients with no HLA-B*15:02 alleles or negative for the HLA-B*15:02 test.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of the absence of HLA-B*15:02 alleles on lamotrigine."
      ],
      "lookupKey": {
        "HLA-B": "*15:02 negative"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    }
  ],
  "citations": [],
  "version": "2023-12-19-10-38"
}